Novavax Shares Surge on $1.4 Billion Vaccine Licensing Deal with Sanofi
By Dean Seal
Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi.
The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in positive territory year-to-date.
The vaccine maker said overnight that it has reached a licensing agreement with Sanofi to jointly commercialize its current Covid-19 vaccine worldwide and provide Sanofi with a sole license to its vaccine for use in combination with Sanofi's flu vaccine.
As part of the deal, Sanofi will take a minority equity investment in Novavax.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
May 10, 2024 06:59 ET (10:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
After Earnings, Is MongoDB Stock a Buy, a Sell, or Fairly Valued?
-
Where We See Opportunities in June as Stocks Recover Losses
-
10 Top-Performing Dividend Stocks of the Month
-
10 Cheap Dividend-Growth Stocks to Buy
-
Manager: Nvidia Will Be Biggest Company in the World
-
The Best Utilities Stocks to Buy
-
3 Cheap Dividend Stocks to Buy Yielding 4% or More
-
After Earnings, Is Salesforce Stock a Buy, Sell, or Fairly Valued?